--- title: "U.S. stock market midday update: Neuronetics up 25.93%, driven by dual engines of AI demand and profit expectations" type: "News" locale: "en" url: "https://longbridge.com/en/news/293228983.md" description: "Neuronetics rose 25.93%; Intuitive Surgical rose 0.17%, with a transaction volume of USD 546 million; Abbott rose 0.22%, with a transaction volume of USD 235 million; Boston Scientific fell 0.40%, with a transaction volume of USD 9.179 million; Stryker fell 0.23%, with a market value of USD 122.3 billion" datetime: "2026-07-20T14:32:49.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293228983.md) - [en](https://longbridge.com/en/news/293228983.md) - [zh-HK](https://longbridge.com/zh-HK/news/293228983.md) --- # U.S. stock market midday update: Neuronetics up 25.93%, driven by dual engines of AI demand and profit expectations **U.S. Stock Market Midday Update** Neuronetics rose 25.93%. Based on recent key news: 1. On July 19, Neuronetics' stable operations in the medical device sector attracted market attention. Despite relatively stable trading recently, its robust performance in the industry drew investor interest, driving the stock price up by 25.93%. Source: Zhitong Finance 2. On July 18, the increasing demand for AI infrastructure pushed the stock prices of related companies higher. As a medical device manufacturer, Neuronetics benefited from investors' preference for companies with stable cash flow, resulting in a significant rise in its stock price. Source: Wall Street Insight 3. On July 17, analysts held an optimistic view on Neuronetics' profitability, expecting its future performance to continue growing. The positive evaluations from analysts enhanced market confidence, further driving the stock price up. Source: Jinshi Data, increased demand in the medical device industry, with significant capital inflow. **Stocks with High Trading Volume in the Industry** Intuitive Surgical rose 0.17%. Based on recent news, 1. On July 17, Intuitive Surgical announced its second-quarter financial report, with revenue and profit exceeding market expectations. However, the company maintained its full-year surgical volume growth outlook, disappointing investors, leading to a post-market plunge of over 11%. Second-quarter revenue grew 19% year-on-year to $2.89 billion, with adjusted earnings per share of $2.80, and total surgical volume for the global da Vinci and Ion platforms increased by 16%. 2. On July 17, Citigroup analysts pointed out that despite the impressive performance, the company's failure to raise its full-year outlook disappointed the market, raising concerns about the slowdown in the U.S. market growth. Second-quarter U.S. da Vinci surgical volume grew by 12%, lower than the company's expectations at the beginning of the year, with some patients delaying treatment due to changes in insurance coverage and premiums. 3. On July 17, Piper Sandler lowered Intuitive Surgical's target price from $580 to $470, maintaining an "Overweight" rating. Analysts believe that despite the company's performance exceeding expectations, market concerns about the slowdown in surgical volume growth overshadowed this highlight. Competition in the surgical robotics industry is intensifying, and market growth is slowing. Abbott rose 0.22%, with increased trading volume. Based on recent news, 1. On July 16, Abbott reported second-quarter sales of $12.6 billion, exceeding market expectations of $12.5 billion, with adjusted earnings per share of $1.31, also surpassing expectations. The company raised its full-year earnings per share forecast to $5.45 to $5.60, driving the stock price up. 2. On July 17, JP Morgan raised Abbott's target price from $110 to $120, maintaining an "Overweight" rating, further boosting market confidence. 3. On July 17, Citigroup raised Abbott's target stock price from $108 to $112, with analysts generally optimistic about Abbott's future performance. The medical technology industry has performed strongly recently, enhancing market confidence Boston Scientific fell 0.40%, with a transaction amount reaching $917.9 million, and trading volume increased, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks ranked at the top of the industry market capitalization** Stryker fell 0.23%. Based on recent key news: 1. On July 18, concerns about the long-term effects of GLP-1 weight loss drugs raised market worries, potentially leading to a decrease in obesity-related orthopedic surgeries, especially knee and hip replacements. Such concerns have caused stock price fluctuations. Source: MarketBeat 2. On July 18, fluctuations in the dollar exchange rate have intensified the currency conversion risks for Stryker's international business, which may affect revenue growth and adjusted earnings per share in future fiscal quarters. Source: MarketBeat 3. On July 18, ongoing monitoring of FDA 510(k) certification and potential Class II recall risks pose threats to the MedSurg and Neurotechnology sectors, which may lead to supply chain disruptions and market share losses. Source: MarketBeat The healthcare industry faces policy and exchange rate risks ### Related Stocks - [STIM.US](https://longbridge.com/en/quote/STIM.US.md) - [ISRG.US](https://longbridge.com/en/quote/ISRG.US.md) - [ABT.US](https://longbridge.com/en/quote/ABT.US.md) - [BSX.US](https://longbridge.com/en/quote/BSX.US.md) - [SYK.US](https://longbridge.com/en/quote/SYK.US.md) ## Related News & Research - [Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength](https://longbridge.com/en/news/295533190.md) - [Neuronetics publishes investor presentation on NeuroStar TMS, Greenbrook clinic network strategy](https://longbridge.com/en/news/295534982.md) - [Why Is Neuronetics Stock Soaring Monday?](https://longbridge.com/en/news/293245736.md) - [Neuronetics 10% owner Jorey Chernett buys 35,000 common shares worth $62,300](https://longbridge.com/en/news/292776470.md) - [Neuronetics Reports First Quarter 2026 Financial and Operating Results | STIM Stock News](https://longbridge.com/en/news/285200182.md)